METHODS: The study was conducted in Kinshasa, the Democratic Republic of Congo between January 2002 and December 2012.
RESULTS: A total of 63 cases of pediatric non-Hodgkin\'s lymphoma were retrospectively analyzed. This cohort represents the largest series of pediatric non-Hodgkin\'s lymphoma presented from sub-Saharan Africa. Median age was 8.7±3.6 years. There were 43 (68.3%) males. A mean of 82 ± 59 days passed from detection of the first sign to referral to oncology unit. Morphology distribution showed that 42 cases (66.7%) had a diagnosis of Burkitt lymphoma, 16 cases (25.4%) had diffuse large B-cell lymphoma and 5 cases (7.9%) had NHL-not otherwise specified. The majority of patients (82.5%) had advanced stage (stage III and IV). Immunohistochemistry findings were available for 32 biopsy samples. All (100%) cases were B-cell non-Hodgkin\'s lymphoma and immunohistochemistry had identified 18 (56.3%) cases of Burkitt lymphoma. In our cohort, 22 of 32 cases expressed positive bcl-2 and 12 (37.5%) were found to be positive for bcl-6. Thirty-one (96.7%) cases were positive for high Ki-67 antigen expression. Assuming that cases lost to follow-up worsened and died, the mortality would be 98.4%.
CONCLUSIONS: In comparison to western data, we observed higher proportion of B-cell non-Hodgkin\'s lymphoma, Burkitt Lymphoma and patients with bcl-2 expression.
方法:这项研究是在金沙萨进行的,2002年1月至2012年12月期间的刚果民主共和国。
结果:回顾性分析63例小儿非霍奇金淋巴瘤。该队列代表了撒哈拉以南非洲最大的儿科非霍奇金淋巴瘤系列。中位年龄为8.7±3.6岁。男性43人(68.3%)。从检测到第一个体征到转诊到肿瘤科的平均时间为82±59天。形态分布显示42例(66.7%)诊断为Burkitt淋巴瘤,16例(25.4%)患有弥漫性大B细胞淋巴瘤,5例(7.9%)患有非霍奇金淋巴瘤。大多数患者(82.5%)为晚期(III期和IV期)。免疫组织化学结果可用于32个活检样品。所有(100%)病例均为B细胞非霍奇金淋巴瘤,免疫组织化学鉴定出18例(56.3%)Burkitt淋巴瘤。在我们的队列中,32例中有22例表达bcl-2阳性,12例(37.5%)表达bcl-6阳性。31例(96.7%)Ki-67抗原高表达阳性。假设失去随访的病例恶化并死亡,死亡率为98.4%。
结论:与西方数据相比,我们观察到B细胞非霍奇金淋巴瘤的比例更高,伯基特淋巴瘤与bcl-2表达的关系.